Pfizer's RSV Vaccine Abrysvo Shows Positive Response After Single Dose
By Michael Susin
Pfizer on Monday said that top-line data from a late-stage study regarding its vaccine for respiratory syncytial virus, or RSV, showed that the treatment generated strong neutralizing responses after a single dose in adults.
The company said the Phase 3 study evaluating two doses of Abrysvo versus placebo in adults with immunocompromising conditions who are at risk of developing severe RSV-associated lower respiratory tract disease, showed that a single dose of the drug generated strong neutralizing response across all cohorts and age groups. The drug was also well tolerated during the trial, showing a safety profile consistent with other studies of the vaccine.
Pfizer said it plans to share these findings at an upcoming scientific conference and to submit these data to the regulatory agencies for review.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
August 12, 2024 07:32 ET (11:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States